Maryland biopharma company Precigen Inc. said Tuesday it reached a deal to sell animal reproductive technologies company Trans Ova Genetics LC to URUS Group LP, an agriculture holding company based in Madison, for $170 million in cash.

The deal also includes up to $10 million in performance-based earnouts if Trans Ova achieves certain benchmarks in 2022 and 2023. The transaction is expected to close in the third quarter.

Helen Sabzevari, president and CEO of Germantown, Maryland-based Precigen (Nasdaq: PGEN), said in a statement the deal was made to commit more of the company’s focus to the “rapid development of our top clinical assets” in the cell and gene therapy space.

Click here to read the full article.